By Fineline Cube The National Medical Products Administration (NMPA), together with the Ministry of Public Security and the National Health Commission, jointly issued an announcement adjusting the Schedule of Medicinal Psychotropic Drugs. Effective October 1, 2026, metomidate (excluding pharmaceutical preparations containing metomidate approved for marketing within China), lometomidate (excluding approved domestic preparations), and solriamfetol will be added to the schedule — tightening oversight of three psychoactive compounds while preserving access for legally marketed medicines.
Regulatory Adjustment at a Glance
| Item | Detail |
|---|---|
| Issuing Authorities | National Medical Products Administration (NMPA), Ministry of Public Security, National Health Commission |
| Action Type | Adjustment to the Schedule of Medicinal Psychotropic Drugs |
| Substances Added | Metomidate, lometomidate, solriamfetol |
| Exclusions | Pharmaceutical preparations containing metomidate or lometomidate approved for marketing within China |
| Effective Date | October 1, 2026 |
Scope & Implementation Notes
- Targeted scheduling: The adjustment schedules the raw substances metomidate, lometomidate, and solriamfetol as medicinal psychotropic drugs, subjecting them to China’s controlled‑substance management framework
- Marketing carve‑out: Domestically approved pharmaceutical preparations containing metomidate or lometomidate are explicitly excluded, ensuring continuity of supply for legitimate clinical use
- Three‑agency coordination: Joint issuance by the drug regulator, public security authority, and health commission reflects the combined oversight model applied to psychotropic substances in China — covering regulation, enforcement, and clinical governance
- Implementation runway: The roughly one‑month interval between announcement and the October 1, 2026 effective date provides industry stakeholders time to align manufacturing, distribution, and prescription practices with the new schedule
Market Impact & Outlook
- Tighter control of psychoactive substances: Adding metomidate, lometomidate, and solriamfetol to the psychotropic drug schedule strengthens supervision against misuse while formalizing their status within the medicinal framework
- Continuity for approved products: The explicit exclusion of domestically approved preparations shields incumbent manufacturers of metomidate‑ and lometomidate‑containing medicines from supply disruption, though compliance and traceability requirements may still increase
- Import and development implications: For solriamfetol — a wakefulness‑promoting agent approved in overseas markets — scheduling status becomes a key consideration for any future China registration strategy
- Policy signal: The adjustment continues China’s pattern of proactively updating psychotropic schedules in response to emerging substance‑use risks, aligning medicinal access with public‑safety enforcement
Forward‑Looking Statements — This brief describes a regulatory policy announcement and its potential industry implications. Interpretation of scheduling requirements and their commercial effects involves uncertainty; companies should consult the official joint announcement from the NMPA, Ministry of Public Security, and National Health Commission for definitive requirements. No investment decision should be made solely on the basis of this brief.-Fineline Info & Tech